Actelion buyout could reach $9.8B, Bloomberg figures

Bloomberg sat down to crunch the numbers on a potential takeover of Switzerland's Actelion and concluded that the biotech could fetch around $9.8 billion if Amgen ($AMGN) or some other suitor swoops in to take it over. Report

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.